Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MREO Relative to the S&P 500

MREO Relative to the Sector

Seasonal Chart Analysis

Analysis of the Mereo BioPharma Group Plc (NASD:MREO) seasonal charts above shows that a Buy Date of January 23 and a Sell Date of June 20 has resulted in a geometric average return of 30.97% above the benchmark rate of the S&P 500 Total Return Index over the past 5 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 5 years by an average of 39.64% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 5 years of data is available for shares of MREO, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

To download MREO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MREO